Laboratorio SIFO di Farmacoeconomia, Careggi Hospital, Florence, Italy.
Clin Drug Investig. 2003;23(4):225-32. doi: 10.2165/00044011-200323040-00002.
To evaluate the cost-effectiveness profile of topiramate as adjunctive treatment in patients with refractory epilepsy.
Lifetime cost-utility analysis based on a pharmacoeconomic model.
Effectiveness data (seizure frequency reduction) were derived from the most recent placebo-controlled clinical trial, whilst quality of life and cost data were retrieved from the published literature. Our pharmacoeconomic model was based on a patient-level approach that incorporated the clinical data of the randomised, controlled trial.
Our analysis showed that chronic topiramate treatment costs pound21 353 per quality-adjusted life year (QALY) gained (incremental lifetime cost of pound1 024 941 and incremental utility of 48 QALYs, for every 100 patients) [discounted values with a yearly rate of 3%] (year of costing 2001). Sensitivity analyses suggested a range from pound19 915 to pound24 518 per QALY gained.
Our results showed that adjunctive topiramate therapy has a favourable pharmacoeconomic profile in patients with refractory epilepsy.
评估托吡酯作为难治性癫痫辅助治疗的成本效益情况。
基于药物经济学模型的终生成本-效用分析。
有效性数据（癫痫发作频率降低）源自最近的安慰剂对照临床试验，而生活质量和成本数据则从已发表的文献中获得。我们的药物经济学模型基于患者水平的方法，纳入了随机对照试验的临床数据。
我们的分析表明，慢性托吡酯治疗的成本为每获得 1 个质量调整生命年（QALY）需要 21353 英镑（每 100 例患者的终身增量成本为 1024941 英镑，增量效用为 48QALY）[贴现率为 3%（成本计价年为 2001 年）]。敏感性分析表明，每获得 1 个 QALY 的成本在 19915 英镑至 24518 英镑之间。
我们的研究结果表明，托吡酯辅助治疗在难治性癫痫患者中有良好的药物经济学效益。
